HC Wainwright Has Pessimistic Outlook of Valneva Q4 Earnings

Valneva SE (NASDAQ:VALN) – HC Wainwright cut their Q4 2024 earnings estimates for shares of Valneva in a research note issued on Wednesday, February 19th. HC Wainwright analyst E. White now expects that the company will post earnings of ($0.17) per share for the quarter, down from their previous forecast of ($0.15). HC Wainwright currently has a “Buy” rating and a $17.00 target price on the stock. The consensus estimate for Valneva’s current full-year earnings is $0.13 per share. HC Wainwright also issued estimates for Valneva’s Q1 2025 earnings at ($0.40) EPS, Q2 2025 earnings at ($0.29) EPS, Q3 2025 earnings at ($0.33) EPS, Q4 2025 earnings at ($0.33) EPS, FY2025 earnings at ($1.36) EPS, FY2026 earnings at ($1.23) EPS and FY2027 earnings at ($1.28) EPS.

Valneva Stock Performance

Shares of VALN stock opened at $7.91 on Friday. Valneva has a 12-month low of $3.62 and a 12-month high of $9.50. The business’s 50 day moving average is $5.18 and its two-hundred day moving average is $5.67. The company has a current ratio of 2.78, a quick ratio of 2.25 and a debt-to-equity ratio of 0.70.

Hedge Funds Weigh In On Valneva

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. ABC Arbitrage SA acquired a new stake in Valneva during the 4th quarter worth $84,000. AlphaCentric Advisors LLC increased its position in Valneva by 33.7% during the third quarter. AlphaCentric Advisors LLC now owns 118,000 shares of the company’s stock worth $717,000 after purchasing an additional 29,748 shares during the last quarter. Finally, Wells Fargo & Company MN raised its stake in Valneva by 14.3% during the fourth quarter. Wells Fargo & Company MN now owns 246,766 shares of the company’s stock worth $1,079,000 after purchasing an additional 30,859 shares during the period. 11.39% of the stock is owned by hedge funds and other institutional investors.

About Valneva

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.